Sangart, Inc. Reports Positive Phase IIa Data For Novel Oxygen Therapeutic Agent MP4OX In Severe Trauma Patients
SAN DIEGO, August 31, 2010 /PRNewswire/ -- Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured…